据介绍，百奥赛图通过“千鼠万抗”抗体分子库和DeepSeek平台的结合，可为全球药企提供全新的单抗、双抗和多抗分子骨架。这些分子骨架具有高亲和力、低免疫原性和优异的成药性。借助DeepSeek平台，全球药企可以从“千鼠万抗”真实存在的千万级别抗体分子库中，快速筛选出具有极高成药潜力的目标抗体分子。DeepSeek 还可以通过模拟分子相互作用，借助“千鼠万抗”庞大抗体分子库筛选获得分子骨架，快速设计出具有特定功能的多特异性抗体，如双抗和多抗等，快速开发出针对各种疾病的创新抗体药物，大大加速药物研发进程，满足未被满足的临床需求。Bai Aosaitu-B (02315) rose over 10% against the market trend, up 10.07% as of the report, trading at 12.02 HKD, with a transaction volume of 0.1252 million HKD.
According to Zhitong Finance APP, Bai Aosaitu-B (02315) rose over 10% against the market trend, up 10.07% as of the report, trading at 12.02 HKD, with a transaction volume of 0.1252 million HKD.
In terms of news, Bai Aosaitu-B announced that the company recently completed the localization deployment of the AI-driven antibody drug research and development platform DeepSeek, and achieved full synergy with the company's core Business 'Thousands of Mice and Ten Thousand Antibodies' program. This technological integration marks a new phase in the early research and development field of antibody drugs towards intelligence and data, which will provide Global pharmaceutical companies with more precise and breakthrough antibody drug research and development solutions, greatly accelerating the drug development process.
It is reported that Bai Aosaitu, through the combination of the 'Thousands of Mice and Ten Thousand Antibodies' antibody molecular library and the DeepSeek platform, can provide Global pharmaceutical companies with a new single antibody, dual antibody, and multi-antibody molecular framework. These molecular frameworks feature high affinity, low immunogenicity, and excellent drug-like properties. Utilizing the DeepSeek platform, Global pharmaceutical companies can quickly screen high drug-like potential target antibody molecules from the tens of millions of real antibody molecular library of 'Thousands of Mice and Ten Thousand Antibodies'. DeepSeek can also simulate molecular interactions and select molecular frameworks from the vast antibody molecular library of 'Thousands of Mice and Ten Thousand Antibodies' to rapidly design multifunctional antibodies with specific capabilities, such as dual and multi-antibodies, quickly developing innovative antibody drugs for various diseases, greatly accelerating the drug development process, and meeting unmet clinical needs.
Today, after hitting the high near 24,000 in the early session and entering bearish positions, the index fell sharply by nearly over 600 points, immediately recouping yesterday's losses significantly.
Moreover, today it broke the new high again, reaching a maximum of 24,076, but by the end of the market, it fell back by about 70 points, producing a bearish candle. The current trend has not yet been broken, but from the previous low until now, it has risen close to 6,000 points. It is believed that those with positions can continue to hold until there is a clear trend reversal for profit-taking. Those without positions can wait for a pullback to get in. Actually, it is hoped for a quick pullback, as it allows for entry and also provides a healthy breath.
Currently, the outlook remains the same as before. It is believed that even if there is a pullback, it shouldn't be too deep. However, if Futures fail to stabilize and close below 22,350, there may still be room for decline. The chance of Futures falling below 21,400 in the short term should be low, so it is considered that if a significant pullback occurs, it presents a good opportunity to incrementally go long. Recently, there has been a consistent approach to not hold positions overnight, only focusing on immediate trades, as there is no high chasing and no casual short selling.
Comment(0)
Reason For Report